Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer
Proposed prognostic score models may facilitate identifying patient subsets at higher risk of AR to 1L anti-PD-(L)1.
Authors
- Adam J. Schoenfeld (ORCID: https://orcid.org/0000-0002-2644-1416)
- Chen Hu (ORCID: https://orcid.org/0000-0003-4672-1981)
- Jeffrey C. Murray (ORCID: https://orcid.org/0000-0001-6346-6551)
- Carlos King Ho Wong (ORCID: https://orcid.org/0000-0002-6895-6071)
- L.C. Villaruz
- Ying-Cheng Chen (ORCID: https://orcid.org/0000-0002-3344-6266)
- Rachael L. DiSantostefano (ORCID: https://orcid.org/0000-0002-5324-6835)
- Qingyuan Huang (ORCID: https://orcid.org/0000-0003-4389-6188)
- Aisha Hasan (ORCID: https://orcid.org/0000-0003-4540-6904)
- E. Curran
- L. Glatz
Institutions
- Johnson & Johnson (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- Cornell University (US)
- UPMC Hillman Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Pittsburg State University (US)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100148
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Johnson and Johnson
- Johnson and Johnson Pharmaceutical Research and Development